

Andrea Boutros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4950648/publications.pdf>

Version: 2024-02-01

12
papers

339
citations

1040056

9
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

483
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2022, 37, 954-968.	0.9	41
2	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 1388.	3.7	22
3	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. <i>BMC Cancer</i> , 2021, 21, 425.	2.6	16
4	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. <i>Frontiers in Oncology</i> , 2021, 11, 739006.	2.8	12
5	How to Protect Ovarian Function before and during Chemotherapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4192.	2.4	11
6	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 159, 154-166.	2.8	19
7	New Melanoma Staging: Prognostic Factors. <i>Updates in Surgery Series</i> , 2021, , 47-53.	0.1	0
8	Current State of Target Treatment in BRAF Mutated Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 154.	3.5	82
9	Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 653-662.	4.2	16
10	Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 403-413.	2.4	2
11	The adjuvant treatment revolution for high-risk melanoma patients. <i>Seminars in Cancer Biology</i> , 2019, 59, 283-289.	9.6	40
12	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2019, 59, 290-297.	9.6	78